Logo image of NGNE

NEUROGENE INC (NGNE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NGNE - US64135M1053 - Common Stock

20.16 USD
-0.44 (-2.14%)
Last: 1/2/2026, 8:00:01 PM
20.16 USD
0 (0%)
After Hours: 1/2/2026, 8:00:01 PM
Fundamental Rating

3

Overall NGNE gets a fundamental rating of 3 out of 10. We evaluated NGNE against 530 industry peers in the Biotechnology industry. NGNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NGNE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NGNE had negative earnings in the past year.
In the past year NGNE has reported a negative cash flow from operations.
NGNE had negative earnings in each of the past 5 years.
In the past 5 years NGNE always reported negative operating cash flow.
NGNE Yearly Net Income VS EBIT VS OCF VS FCFNGNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -26.11%, NGNE is in the better half of the industry, outperforming 70.57% of the companies in the same industry.
The Return On Equity of NGNE (-28.30%) is better than 77.74% of its industry peers.
Industry RankSector Rank
ROA -26.11%
ROE -28.3%
ROIC N/A
ROA(3y)-29.45%
ROA(5y)-28.26%
ROE(3y)-34.92%
ROE(5y)-32.93%
ROIC(3y)N/A
ROIC(5y)N/A
NGNE Yearly ROA, ROE, ROICNGNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

NGNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGNE Yearly Profit, Operating, Gross MarginsNGNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

NGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
NGNE has more shares outstanding than it did 1 year ago.
NGNE has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NGNE has been reduced compared to a year ago.
NGNE Yearly Shares OutstandingNGNE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
NGNE Yearly Total Debt VS Total AssetsNGNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

NGNE has an Altman-Z score of 6.93. This indicates that NGNE is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.93, NGNE is in the better half of the industry, outperforming 76.79% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that NGNE is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, NGNE perfoms like the industry average, outperforming 53.02% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.93
ROIC/WACCN/A
WACC8.83%
NGNE Yearly LT Debt VS Equity VS FCFNGNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 18.39 indicates that NGNE has no problem at all paying its short term obligations.
The Current ratio of NGNE (18.39) is better than 95.28% of its industry peers.
NGNE has a Quick Ratio of 18.39. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NGNE (18.39) is better than 95.28% of its industry peers.
Industry RankSector Rank
Current Ratio 18.39
Quick Ratio 18.39
NGNE Yearly Current Assets VS Current LiabilitesNGNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.20% over the past year.
EPS 1Y (TTM)14.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NGNE will show a very negative growth in Earnings Per Share. The EPS will decrease by -12.73% on average per year.
The Revenue is expected to grow by 131.75% on average over the next years. This is a very strong growth
EPS Next Y-0.23%
EPS Next 2Y-11.54%
EPS Next 3Y-12.73%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y131.75%

3.3 Evolution

NGNE Yearly Revenue VS EstimatesNGNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2029 2030 2031 2032 200M 400M 600M 800M
NGNE Yearly EPS VS EstimatesNGNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NGNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGNE Price Earnings VS Forward Price EarningsNGNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGNE Per share dataNGNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as NGNE's earnings are expected to decrease with -12.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.54%
EPS Next 3Y-12.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NGNE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

NEUROGENE INC

NASDAQ:NGNE (1/2/2026, 8:00:01 PM)

After market: 20.16 0 (0%)

20.16

-0.44 (-2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners104.75%
Inst Owner Change0%
Ins Owners8.5%
Ins Owner Change0%
Market Cap312.28M
Revenue(TTM)925.00K
Net Income(TTM)-75.14M
Analysts86.67
Price Target60.18 (198.51%)
Short Float %24.97%
Short Ratio15.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.75%
Min EPS beat(2)11.15%
Max EPS beat(2)22.35%
EPS beat(4)4
Avg EPS beat(4)12.01%
Min EPS beat(4)0.42%
Max EPS beat(4)22.35%
EPS beat(8)6
Avg EPS beat(8)4.78%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)24.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.27%
EPS NY rev (1m)0%
EPS NY rev (3m)11.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 337.6
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)-4.11
EYN/A
EPS(NY)-5.31
Fwd EYN/A
FCF(TTM)-5.06
FCFYN/A
OCF(TTM)-4.99
OCFYN/A
SpS0.06
BVpS17.14
TBVpS17.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.11%
ROE -28.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.45%
ROA(5y)-28.26%
ROE(3y)-34.92%
ROE(5y)-32.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.37%
Cap/Sales 126.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.39
Quick Ratio 18.39
Altman-Z 6.93
F-Score3
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)35.41%
Cap/Depr(5y)127.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.81%
EPS Next Y-0.23%
EPS Next 2Y-11.54%
EPS Next 3Y-12.73%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y131.75%
EBIT growth 1Y-48.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-138.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.25%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROGENE INC / NGNE FAQ

What is the fundamental rating for NGNE stock?

ChartMill assigns a fundamental rating of 3 / 10 to NGNE.


What is the valuation status of NEUROGENE INC (NGNE) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUROGENE INC (NGNE). This can be considered as Overvalued.


Can you provide the profitability details for NEUROGENE INC?

NEUROGENE INC (NGNE) has a profitability rating of 1 / 10.


Can you provide the financial health for NGNE stock?

The financial health rating of NEUROGENE INC (NGNE) is 6 / 10.